FDA recall D-0166-2025 · initiated Nov 14, 2024
May cause temporary or medically reversible harm; low probability of serious harm.
cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.